
Neuroscience Evidence Brief Builder
Synthesize neuroscience research into field-ready evidence briefs for HCP engagement
What You Can Do
You transform raw neuroscience research—Phase II/III trials, real-world evidence, meta-analyses, and safety data—into production-quality evidence briefs organized by clinical relevance and HCP objection type. The skill synthesizes complex methodologies and results into clear clinical implications, generates competitive positioning documents with transparent advantage mapping, and pre-builds responses to predictable HCP questions grounded in published evidence. This cuts 6-10 hours of manual literature review per field visit cycle while maintaining regulatory compliance and scientific rigor.
Features
Distill Phase II/III trials, RWE, and meta-analyses into 1-2 page briefs with key findings, limitations, and clinical implications
Extract head-to-head trial data and comparative safety profiles; create transparent advantage/limitation matrices against competing therapies
Generate pre-built responses to predictable objections based on indication, HCP specialty, and published evidence with regulatory citations
Organize briefs by indication, mechanism, safety concern, or competitor; generate priority-ranked HCP talking points for 48-72 hour prep cycles
Flag publication type (RCT, observational, case series), sample size, and regulatory status to guide credibility and field communication tone
Embed FDA/EMA guidance references and ensure claims align with approved labeling and published post-market surveillance data
Log new publications, trial outcomes, and competitor claims; flag gaps in your evidence portfolio and emerging HCP concerns
Example Output
Clinical Evidence Brief Example
Study: Phase III PARADIGM-Neuro Trial (2023)
Primary Finding: 34% reduction in disease progression vs. placebo (p<0.001)
Key Limitations: Younger patient population (mean age 52); 12-week follow-up only
HCP Talking Point: "Demonstrated sustained efficacy in early-stage disease; longest controlled trial in mechanism class to date."
Competitive Positioning Matrix
| Factor | Your Therapy | Competitor A | Competitor B |
|---|---|---|---|
| Onset | 2-3 weeks | 4-6 weeks | 1 week |
| Safety Profile | Well-tolerated (GI class) | Hepatotoxicity signal | Rare but severe CNS events |
| Patient Population | Mild-to-moderate | Moderate-to-severe | All severity |
| Advantage | Fast onset + favorable tolerability | — | — |
HCP Question Anticipation
Q: "How does this compare to the recent head-to-head trial?"
A: "That study compared our therapy to [Competitor] in moderate disease. Our Phase III enrolled earlier-stage patients where we showed superior tolerability. Different populations, but our safety advantage holds across severity levels per post-market data."
What's Included
- SKILL.md: Complete instruction file with overview, use-case triggers, and skill configuration
- Evidence Brief Template: Pre-formatted structure with sections for study design, results, limitations, and clinical implication statements
- HCP Question Bank: 25+ predicted objections by indication (e.g., efficacy, safety, access, cost) with evidence-backed response frameworks
- Competitive Positioning Framework: Matrix template for multi-therapy comparison with regulatory and RWE data integration
- Field Visit Preparation Checklist: Priority-ranked brief organization system for 48-72 hour pre-visit cycles with talking-point prioritization
- Evidence Grading Reference: Quick-lookup guide for publication type credibility ranking and tone calibration for field use
Who It's For
- Medical Science Liaisons (Neuroscience) — Prepare accurate, evidence-rich HCP talking points and differentiation narratives for field interactions
- Clinical Directors — Develop competitive intelligence summaries and evidence portfolios for therapy positioning and market monitoring
- Regulatory Affairs Specialists — Ensure field communications remain compliant with approved labeling and post-market data
- Commercial Strategy Teams — Build evidence-based launch narratives and identify gaps in clinical data relevant to market positioning
- Medical Affairs Managers — Oversee field preparation workflows and ensure consistent, scientifically rigorous HCP engagement
Best For
- Pre-field visit preparation — Synthesize latest publications and competitive threats 48-72 hours before HCP interactions
- Competitive threat response — Rapidly develop evidence-based differentiation messaging when competitors launch or publish head-to-head trials
- Indication-specific talking point development — Build HCP engagement scripts grounded in Phase III data, safety profiles, and real-world evidence
- Safety signal communication — Organize post-market surveillance data into transparent brief format that addresses HCP safety concerns without compromising credibility
- New publication integration — Update field materials with latest clinical evidence and regenerate HCP question anticipation guides as new trials publish







